FBL and systemic sclerosis: In addition to the successful analytical validation, Fibrillarin/CBA results were associated with disease phenotypes expected in anti-fibrillarin positive SSc, namely severe manifestations of SSc including diffuse cutaneous involvement, cardiac and renal involvement.